What is Atox Bio?
Atox Bio operates at the intersection of advanced biotechnology and wellness, specializing in the development and distribution of high-quality therapeutic products. The company has carved out a distinct niche by providing verified injectable treatments, including human growth hormone (HGH) therapies, tailored for both pediatric and adult populations. By prioritizing safety, transparency, and clinical effectiveness, Atox Bio addresses the needs of a diverse demographic, ranging from fitness enthusiasts to individuals requiring specialized medical support. Its operational model is built upon a foundation of trust, ensuring that all products meet stringent quality standards while offering personalized support to its client base. This commitment to excellence has allowed the firm to differentiate itself in a competitive market, effectively bridging the gap between academic innovation and commercial accessibility.
How much funding has Atox Bio raised?
Atox Bio has raised a total of $56.3M across 3 funding rounds:
Series A
$3.3M
Series E
$23M
Series F
$30M
Series A (2011): $3.3M with participation from Esperante Ventures
Series E (2014): $23M led by SR One, Lundbeckfond Ventures, and OrbiMed
Series F (2017): $30M supported by SR One, OrbiMed, Adams Street Partners, Arix Bioscience, Integra Holdings, and Asahi Kasei Corporation
Key Investors in Atox Bio
SR One
A transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics, providing both capital and operational support.
OrbiMed
A specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms with deep industry expertise.
Adams Street Partners
A global private markets investment management firm founded in 1972, providing institutional-grade capital and strategic oversight to high-growth enterprises.
What's next for Atox Bio?
With the support of its latest capital injection, Atox Bio is well-positioned to accelerate its strategic initiatives, focusing on the expansion of its therapeutic pipeline and the optimization of its commercial infrastructure. The company is expected to leverage its robust investor network to facilitate further research and development, potentially exploring new frontiers in biotechnology that align with its core competencies. As the firm continues to scale, the emphasis will likely remain on enhancing operational efficiencies and strengthening its market presence through strategic partnerships. By maintaining its focus on high-impact biotech opportunities, Atox Bio is poised to sustain its growth trajectory and continue delivering innovative solutions that address critical health and wellness needs on a global scale.
See full Atox Bio company page
